Welcome to our dedicated page for AIM ImmunoTech news (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on AIM ImmunoTech stock.
AIM ImmunoTech Inc. (NYSE American: AIM) is a pioneering immuno-pharma company based in Ocala, Florida, focused on the research and development of innovative therapeutics aimed at treating a variety of cancers, immune disorders, and viral diseases including COVID-19. The company's flagship product is Ampligen® (rintatolimod), a first-in-class investigational drug that acts as a highly selective TLR3 agonist immuno-modulator with broad-spectrum activity. Ampligen is currently undergoing extensive clinical trials targeting globally important cancers and viral diseases.
AIM ImmunoTech's product portfolio also includes Alferon N Injection, an injectable formulation of natural alpha interferon used to treat a specific category of genital warts, a sexually transmitted disease. Ampligen has shown promising results in the treatment of chronic fatigue syndrome and is being developed for other indications like hepatitis B, HIV, and several cancer types, including renal cell carcinoma, malignant melanoma, non-small cell lung cancer, ovarian cancer, breast cancer, colorectal cancer, urothelial cancer, prostate cancer, and pancreatic cancer.
In recent developments, AIM ImmunoTech announced positive top-line interim data indicating that the combination of Ampligen with Keytruda (pembrolizumab) could be significantly more effective than pembrolizumab alone in treating recurrent ovarian cancer. The company is also working on various clinical trials, including studies for treating post-COVID conditions and long COVID, led by renowned medical experts like Dr. Charles Lapp.
AIM ImmunoTech has formed strategic research agreements with prominent institutions such as the Japanese National Institute of Infectious Diseases and Shionogi & Co., Ltd., exploring the potential of Ampligen as an adjuvant therapy for COVID-19. The company continues to focus on operational execution and has successfully completed cGMP manufacturing of over 9,000 clinical vials of Ampligen, which is crucial for its ongoing and upcoming clinical trials.
The company's leadership team, headed by CEO Thomas K. Equels, is committed to advancing its pipeline and achieving clinical and commercial success. AIM ImmunoTech engages with its stakeholders through regular updates and CEO Corner segments, providing insights into its clinical programs and financial performance, ensuring transparency and fostering investor confidence.
For more detailed information, visit the official website and connect with AIM ImmunoTech on social media platforms such as X, LinkedIn, and Facebook.
FAQ
What is the current stock price of AIM ImmunoTech (AIM)?
What is the market cap of AIM ImmunoTech (AIM)?
What is AIM ImmunoTech's main focus?
What are AIM ImmunoTech's key products?
What recent achievements has AIM ImmunoTech made?
Who are AIM ImmunoTech's notable partners?
What clinical trials is AIM ImmunoTech currently conducting?
How can investors access AIM ImmunoTech's financial reports?
How does AIM ImmunoTech engage with its stakeholders?
What is the significance of Ampligen in AIM ImmunoTech's portfolio?
Who leads AIM ImmunoTech?
Where can more information about AIM ImmunoTech be found?
